Scielo RSS http://scielo.isciii.es/rss.php?pid=1130-010820150012&lang=es vol. 107 num. 12 lang. es http://scielo.isciii.es/img/en/fbpelogp.gif http://scielo.isciii.es http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200001&lng=es&nrm=iso&tlng=es http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200002&lng=es&nrm=iso&tlng=es Introduction: Capsule endoscopy (CE) in children has limitations based mainly on age. The objective of this consensus was reviewing the scientific evidence. Material and methods: Some experts from the Spanish Society of Gastroenterology (SEPD) and Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition (SEGHNP) were invited to answer different issues about CE in children. These sections were: a) Indications, contraindications and limitations; b) efficacy of CE in different clinical scenarios; c) CE performance; d) CE-related complications; e) Patency capsule; and f) colon capsule endoscopy. They reviewed relevant questions on each topic. Results: The main indication is Crohn's disease (CD). There is no contraindication for the age and in the event that the patient not to swallow it, it should be administered under deep sedation with endoscopy and specific device. The CE is useful in CD, for the management of OGIB in children and in Peutz-Jeghers syndrome (in this indication has the most effectiveness). The main complication is retention, which should be specially taken into account in cases of CD already diagnosed with malnutrition. A preparation regimen based on a low volume of polyethylene glycol (PEG) the day before plus simethicone on the same day is the best one in terms of cleanliness although does not improve the results of the CE procedure. Conclusions: CE is safe and useful in children. Indications are similar to those of adults, the main one is CD to establish both a diagnosis and disease extension. Moreover, only few limitations are detected in children. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200003&lng=es&nrm=iso&tlng=es Objective: The purpose of this study was to assess the resectability and effectiveness of repeat hepatectomy for relapsing liver metastases of colorectal origin in terms of morbidity, mortality, overall survival, and disease-free survival. Methods: A retrospective study was performed on a prospective cohort of patients with colorectal liver metastases who underwent repeat surgery at Hospital Universitario San Cecilio, Granada (Spain), from March 2003 to June 2013. Primary outcome variables included survival and morbidity within 30 days post-surgery. Results: A total of 147 patients with colorectal liver metastases underwent surgical excision during the study period; 61 patients had liver recurrence, and 34 of these received repeat surgery. The overall survival rate at 5 and 10 years for resected patients (n = 27/34) was 48% and 48%. Mean hospital stay was 8.9 ± 3.5 days, morbidity was 9%, and mortality was 0%. Conclusion: Repeat liver resection for colorectal liver metastases is a safe, effective surgical procedure whose results are similar to those obtained after initial liver resection. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200004&lng=es&nrm=iso&tlng=es Background: Liver biopsy, which is considered the best method for evaluating hepatic fibrosis, has important adverse events. Therefore, non-invasive tests have been developed to determine the degree of hepatic fibrosis in patients with chronic hepatitis B. Aim: To verify the usefulness of a new fibrosis index the globulin/platelet model in patients with chronic hepatitis B and to compare it with other noninvasive tests for predicting significant fibrosis. This study was the second to evaluate the globulin/platelet model in HBV patients. Methods: We retrospectively investigated 228 patients with chronic hepatitis B who performed liver biopsy from 2013 to 2014. The globulin/platelet model, APGA [AST/Platelet/Gamma-glutamyl transpeptidase/Alfa-fetoprotein], FIB4, fibrosis index, cirrhosis discriminate score, and Fibro-quotient were calculated, and the diagnostic accuracies of all of the fibrosis indices were compared between the F0-2 (no-mild fibrosis) and F3-6 (significant fibrosis) groups. Results: All of the noninvasive markers were significantly correlated with the stage of liver fibrosis (p < 0,001). To predict significant fibrosis (F ≥ 3), the area under the curve (95% CI) was found to be greatest for APGA (0.83 [0.74-0.86]), followed by FIB-4 (0.75[0.69-0.80]), the globulin/platelet model (0.74 [0.68-0.79]), fibrosis index (0.72 [0.6-0.78], cirrhosis discriminate score (0.71 [0.64-0.76]) and Fibro-quotient (0.62 [0.55-0.7]). The area under the receiver operating characteristic curves of APGA was significantly higher than that of the other noninvasive fibrosis markers (p < 0.05). Conclusions: While the APGA index was found to be the most valuable test for the prediction significant fibrosis in patients with chronic hepatitis B, GP model was the thirth valuable test. Therefore, we recommended that APGA could be used instead of the GP model for prediction liver fibrosis. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200005&lng=es&nrm=iso&tlng=es Introduction: Capsule endoscopy (CE) has become a first-line tool for small bowel (SB) examination. However, adverse events (AEs), such as CE retention or aspiration, may occur. The aims of this study were to evaluate incidence, clinical outcomes and therapeutic approaches of CE-related AEs in the largest series published to date. Methods: Data from 5428 procedures performed at 12 institutions between August 2001 and January 2012 were retrospectively analyzed. Baseline patient characteristics; procedure; type, localization and symptoms before/after AEs; previous patency tests performed; therapeutic management and patient's outcome were recorded. Results: The overall incidence of CE-related AEs was 1.9%: 2.0% for SB, 0.9% for esophageal and 0.5% for colon CE. The incidence of capsule retention was significantly higher than capsule aspiration (1.87% vs. 0.003%; p < 0.05), in patients suffering from inflammatory bowel disease (IBD) than in obscure GI bleeding (OGIB) (3.3% vs. 1.5%; p < 0.05) and in patients with the combination of nausea/vomiting, abdominal pain and distension. The SB was the most frequent localization of retention (88.2%). The use of patency tests -except for Patency© capsule- before CE was not a good predictor for AEs. Most of the patients with AEs developed no or mild symptoms (97%) and were managed by non-surgical methods (64.4%). Conclusions: CE-related AEs are uncommon and difficult to predict by imagiological examinations. SB retention, that is usually asymptomatic, is the most frequent AE. In absence of symptoms, non-surgical management of CE-related AEs is recommended. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200006&lng=es&nrm=iso&tlng=es Background and aims: There are contradictory findings regarding long-term outcome in patients with obscure gastrointestinal bleeding and negative capsule endoscopy. Factors associated with rebleeding after a negative videocapsule are not entirely known. Objective: The aim of this study was to compare the rebleeding rate between negative and positive capsule endoscopy patients and to identify predictive factors for rebleeding in patients with negative findings. Material and methods: Consecutive patients with obscure gastrointestinal bleeding referred to a single center over a period of 5 years were identified. After exclusion of patients with a follow time < 6 months, 173 patients were included. Clinical information was retrospectively collected from medical records. Rebleeding was defined as evidence of melena/hematochezia, a drop in hemoglobin of ≥ 2 g/dL, or the need for transfusion 30 days after the index episode. Results: The mean age was 61.7 years and 60% were female. The median follow up time was 27 months. Most patients were referred for occult gastrointestinal bleeding (67.1%) while 32.9% were referred for overt bleeding. More than 50% of the patients had negative capsule endoscopy. The rebleeding rate in negative capsule endoscopy is 16%, with a mean follow-up time of 25.8 months and is significantly lower than positive capsule endoscopy (16% vs. 30.2%, p = 0.02). Rebleeding after negative capsule endoscopy is higher in patients who need more transfusions of packet red blood cells before capsule endoscopy (3.0 vs. 0.9, p = 0.024) and have overt bleeding (46% vs. 13.9%, p = 0.03). In 53% of these patients, rebleeding occurs &gt; 12 months after a negative capsule endoscopy. Conclusions: Patients with obscure gastrointestinal bleeding and a negative capsule endoscopy had a significantly lower rebleeding rate and can be safely followed. However, a higher transfusion of red blood cells previous to capsule endoscopy and an overt bleeding are associated with a higher rebleeding. So, it is reasonable to consider that these patients may benefit of at least one year of follow-up. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200007&lng=es&nrm=iso&tlng=es Background and aims: There are contradictory findings regarding long-term outcome in patients with obscure gastrointestinal bleeding and negative capsule endoscopy. Factors associated with rebleeding after a negative videocapsule are not entirely known. Objective: The aim of this study was to compare the rebleeding rate between negative and positive capsule endoscopy patients and to identify predictive factors for rebleeding in patients with negative findings. Material and methods: Consecutive patients with obscure gastrointestinal bleeding referred to a single center over a period of 5 years were identified. After exclusion of patients with a follow time < 6 months, 173 patients were included. Clinical information was retrospectively collected from medical records. Rebleeding was defined as evidence of melena/hematochezia, a drop in hemoglobin of ≥ 2 g/dL, or the need for transfusion 30 days after the index episode. Results: The mean age was 61.7 years and 60% were female. The median follow up time was 27 months. Most patients were referred for occult gastrointestinal bleeding (67.1%) while 32.9% were referred for overt bleeding. More than 50% of the patients had negative capsule endoscopy. The rebleeding rate in negative capsule endoscopy is 16%, with a mean follow-up time of 25.8 months and is significantly lower than positive capsule endoscopy (16% vs. 30.2%, p = 0.02). Rebleeding after negative capsule endoscopy is higher in patients who need more transfusions of packet red blood cells before capsule endoscopy (3.0 vs. 0.9, p = 0.024) and have overt bleeding (46% vs. 13.9%, p = 0.03). In 53% of these patients, rebleeding occurs &gt; 12 months after a negative capsule endoscopy. Conclusions: Patients with obscure gastrointestinal bleeding and a negative capsule endoscopy had a significantly lower rebleeding rate and can be safely followed. However, a higher transfusion of red blood cells previous to capsule endoscopy and an overt bleeding are associated with a higher rebleeding. So, it is reasonable to consider that these patients may benefit of at least one year of follow-up. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200008&lng=es&nrm=iso&tlng=es Background: Endometriosis is a relatively common disease among women with child-bearing potential, and rare before puberty or following menopause. It consists of the presence of hormone-responsive endometrium outside the endometrial cavity. Case report: We report the case of a patient with a rectal lesion, initially approached as a primary rectal malignancy, where histopathology eventually revealed an adenocarcinoma arising from endometrial tissue in the colonic wall. Discussion: Endometriosis has an estimated rated of 10-20%. Sites may be split up into two larger categories - gonadal and extragonadal. The frequency of extragonadal endometriosis in the bowel is estimated to involve 3%-37% of women with pelvic endometriosis, and most lesions are found in the sigmoid colon and rectum. The malignant transformation of endometriotic lesions is estimated between 0.3% and 1% of cases. The gold standard in the diagnosis of intestinal endometriosis is exploratory laparotomy and the pathological study of specimens. Adjuvant radiotherapy and chemotherapy, although used for some patients, have not proven effective.<hr/>Introducción: la endometriosis es una patología relativamente frecuente en mujeres en edad fértil y poco prevalerte en mujeres prepúberes o postmenopáusicas. Caso clínico: presentamos el caso clínico de una mujer de 57 años, con antecedentes de histerectomía y doble anexectomía por endometriosis ovárica, diagnosticada de neoplasia de recto T3N1. Se realizó neoadyuvancia preoperatoria y resección anterior baja, sin complicaciones. La anatomía patológica describía infiltración de la pared rectal por adenocarcinoma pobremente diferenciado de origen ginecológico. Discusión: la endometriosis tiene una prevalencia estimada del 10-20% y su lugar de aparición puede ser variado, tanto gonadal como extragonadal. La frecuencia de endometriosis extragonadal de localización intestinal se estima en un 3-37% de mujeres con endometriosis pélvica, y de estas la mayoría se localizan en colon sigmoide y recto. La transformación maligna de un foco de endometriosis se estima entre el 0,3 y el 1%. El gold estándar para el diagnóstico es la resección y estudio histológico. La radioterapia y quimioterapia adyuvante todavía no ha demostrado su clara utilidad. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200009&lng=es&nrm=iso&tlng=es Background: Endometriosis is a relatively common disease among women with child-bearing potential, and rare before puberty or following menopause. It consists of the presence of hormone-responsive endometrium outside the endometrial cavity. Case report: We report the case of a patient with a rectal lesion, initially approached as a primary rectal malignancy, where histopathology eventually revealed an adenocarcinoma arising from endometrial tissue in the colonic wall. Discussion: Endometriosis has an estimated rated of 10-20%. Sites may be split up into two larger categories - gonadal and extragonadal. The frequency of extragonadal endometriosis in the bowel is estimated to involve 3%-37% of women with pelvic endometriosis, and most lesions are found in the sigmoid colon and rectum. The malignant transformation of endometriotic lesions is estimated between 0.3% and 1% of cases. The gold standard in the diagnosis of intestinal endometriosis is exploratory laparotomy and the pathological study of specimens. Adjuvant radiotherapy and chemotherapy, although used for some patients, have not proven effective.<hr/>Introducción: la endometriosis es una patología relativamente frecuente en mujeres en edad fértil y poco prevalerte en mujeres prepúberes o postmenopáusicas. Caso clínico: presentamos el caso clínico de una mujer de 57 años, con antecedentes de histerectomía y doble anexectomía por endometriosis ovárica, diagnosticada de neoplasia de recto T3N1. Se realizó neoadyuvancia preoperatoria y resección anterior baja, sin complicaciones. La anatomía patológica describía infiltración de la pared rectal por adenocarcinoma pobremente diferenciado de origen ginecológico. Discusión: la endometriosis tiene una prevalencia estimada del 10-20% y su lugar de aparición puede ser variado, tanto gonadal como extragonadal. La frecuencia de endometriosis extragonadal de localización intestinal se estima en un 3-37% de mujeres con endometriosis pélvica, y de estas la mayoría se localizan en colon sigmoide y recto. La transformación maligna de un foco de endometriosis se estima entre el 0,3 y el 1%. El gold estándar para el diagnóstico es la resección y estudio histológico. La radioterapia y quimioterapia adyuvante todavía no ha demostrado su clara utilidad. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200010&lng=es&nrm=iso&tlng=es Background: Endometriosis is a relatively common disease among women with child-bearing potential, and rare before puberty or following menopause. It consists of the presence of hormone-responsive endometrium outside the endometrial cavity. Case report: We report the case of a patient with a rectal lesion, initially approached as a primary rectal malignancy, where histopathology eventually revealed an adenocarcinoma arising from endometrial tissue in the colonic wall. Discussion: Endometriosis has an estimated rated of 10-20%. Sites may be split up into two larger categories - gonadal and extragonadal. The frequency of extragonadal endometriosis in the bowel is estimated to involve 3%-37% of women with pelvic endometriosis, and most lesions are found in the sigmoid colon and rectum. The malignant transformation of endometriotic lesions is estimated between 0.3% and 1% of cases. The gold standard in the diagnosis of intestinal endometriosis is exploratory laparotomy and the pathological study of specimens. Adjuvant radiotherapy and chemotherapy, although used for some patients, have not proven effective.<hr/>Introducción: la endometriosis es una patología relativamente frecuente en mujeres en edad fértil y poco prevalerte en mujeres prepúberes o postmenopáusicas. Caso clínico: presentamos el caso clínico de una mujer de 57 años, con antecedentes de histerectomía y doble anexectomía por endometriosis ovárica, diagnosticada de neoplasia de recto T3N1. Se realizó neoadyuvancia preoperatoria y resección anterior baja, sin complicaciones. La anatomía patológica describía infiltración de la pared rectal por adenocarcinoma pobremente diferenciado de origen ginecológico. Discusión: la endometriosis tiene una prevalencia estimada del 10-20% y su lugar de aparición puede ser variado, tanto gonadal como extragonadal. La frecuencia de endometriosis extragonadal de localización intestinal se estima en un 3-37% de mujeres con endometriosis pélvica, y de estas la mayoría se localizan en colon sigmoide y recto. La transformación maligna de un foco de endometriosis se estima entre el 0,3 y el 1%. El gold estándar para el diagnóstico es la resección y estudio histológico. La radioterapia y quimioterapia adyuvante todavía no ha demostrado su clara utilidad. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200011&lng=es&nrm=iso&tlng=es Background: Endometriosis is a relatively common disease among women with child-bearing potential, and rare before puberty or following menopause. It consists of the presence of hormone-responsive endometrium outside the endometrial cavity. Case report: We report the case of a patient with a rectal lesion, initially approached as a primary rectal malignancy, where histopathology eventually revealed an adenocarcinoma arising from endometrial tissue in the colonic wall. Discussion: Endometriosis has an estimated rated of 10-20%. Sites may be split up into two larger categories - gonadal and extragonadal. The frequency of extragonadal endometriosis in the bowel is estimated to involve 3%-37% of women with pelvic endometriosis, and most lesions are found in the sigmoid colon and rectum. The malignant transformation of endometriotic lesions is estimated between 0.3% and 1% of cases. The gold standard in the diagnosis of intestinal endometriosis is exploratory laparotomy and the pathological study of specimens. Adjuvant radiotherapy and chemotherapy, although used for some patients, have not proven effective.<hr/>Introducción: la endometriosis es una patología relativamente frecuente en mujeres en edad fértil y poco prevalerte en mujeres prepúberes o postmenopáusicas. Caso clínico: presentamos el caso clínico de una mujer de 57 años, con antecedentes de histerectomía y doble anexectomía por endometriosis ovárica, diagnosticada de neoplasia de recto T3N1. Se realizó neoadyuvancia preoperatoria y resección anterior baja, sin complicaciones. La anatomía patológica describía infiltración de la pared rectal por adenocarcinoma pobremente diferenciado de origen ginecológico. Discusión: la endometriosis tiene una prevalencia estimada del 10-20% y su lugar de aparición puede ser variado, tanto gonadal como extragonadal. La frecuencia de endometriosis extragonadal de localización intestinal se estima en un 3-37% de mujeres con endometriosis pélvica, y de estas la mayoría se localizan en colon sigmoide y recto. La transformación maligna de un foco de endometriosis se estima entre el 0,3 y el 1%. El gold estándar para el diagnóstico es la resección y estudio histológico. La radioterapia y quimioterapia adyuvante todavía no ha demostrado su clara utilidad. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200012&lng=es&nrm=iso&tlng=es Background: Endometriosis is a relatively common disease among women with child-bearing potential, and rare before puberty or following menopause. It consists of the presence of hormone-responsive endometrium outside the endometrial cavity. Case report: We report the case of a patient with a rectal lesion, initially approached as a primary rectal malignancy, where histopathology eventually revealed an adenocarcinoma arising from endometrial tissue in the colonic wall. Discussion: Endometriosis has an estimated rated of 10-20%. Sites may be split up into two larger categories - gonadal and extragonadal. The frequency of extragonadal endometriosis in the bowel is estimated to involve 3%-37% of women with pelvic endometriosis, and most lesions are found in the sigmoid colon and rectum. The malignant transformation of endometriotic lesions is estimated between 0.3% and 1% of cases. The gold standard in the diagnosis of intestinal endometriosis is exploratory laparotomy and the pathological study of specimens. Adjuvant radiotherapy and chemotherapy, although used for some patients, have not proven effective.<hr/>Introducción: la endometriosis es una patología relativamente frecuente en mujeres en edad fértil y poco prevalerte en mujeres prepúberes o postmenopáusicas. Caso clínico: presentamos el caso clínico de una mujer de 57 años, con antecedentes de histerectomía y doble anexectomía por endometriosis ovárica, diagnosticada de neoplasia de recto T3N1. Se realizó neoadyuvancia preoperatoria y resección anterior baja, sin complicaciones. La anatomía patológica describía infiltración de la pared rectal por adenocarcinoma pobremente diferenciado de origen ginecológico. Discusión: la endometriosis tiene una prevalencia estimada del 10-20% y su lugar de aparición puede ser variado, tanto gonadal como extragonadal. La frecuencia de endometriosis extragonadal de localización intestinal se estima en un 3-37% de mujeres con endometriosis pélvica, y de estas la mayoría se localizan en colon sigmoide y recto. La transformación maligna de un foco de endometriosis se estima entre el 0,3 y el 1%. El gold estándar para el diagnóstico es la resección y estudio histológico. La radioterapia y quimioterapia adyuvante todavía no ha demostrado su clara utilidad. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015001200013&lng=es&nrm=iso&tlng=es Background: Endometriosis is a relatively common disease among women with child-bearing potential, and rare before puberty or following menopause. It consists of the presence of hormone-responsive endometrium outside the endometrial cavity. Case report: We report the case of a patient with a rectal lesion, initially approached as a primary rectal malignancy, where histopathology eventually revealed an adenocarcinoma arising from endometrial tissue in the colonic wall. Discussion: Endometriosis has an estimated rated of 10-20%. Sites may be split up into two larger categories - gonadal and extragonadal. The frequency of extragonadal endometriosis in the bowel is estimated to involve 3%-37% of women with pelvic endometriosis, and most lesions are found in the sigmoid colon and rectum. The malignant transformation of endometriotic lesions is estimated between 0.3% and 1% of cases. The gold standard in the diagnosis of intestinal endometriosis is exploratory laparotomy and the pathological study of specimens. Adjuvant radiotherapy and chemotherapy, although used for some patients, have not proven effective.<hr/>Introducción: la endometriosis es una patología relativamente frecuente en mujeres en edad fértil y poco prevalerte en mujeres prepúberes o postmenopáusicas. Caso clínico: presentamos el caso clínico de una mujer de 57 años, con antecedentes de histerectomía y doble anexectomía por endometriosis ovárica, diagnosticada de neoplasia de recto T3N1. Se realizó neoadyuvancia preoperatoria y resección anterior baja, sin complicaciones. La anatomía patológica describía infiltración de la pared rectal por adenocarcinoma pobremente diferenciado de origen ginecológico. Discusión: la endometriosis tiene una prevalencia estimada del 10-20% y su lugar de aparición puede ser variado, tanto gonadal como extragonadal. La frecuencia de endometriosis extragonadal de localización intestinal se estima en un 3-37% de mujeres con endometriosis pélvica, y de estas la mayoría se localizan en colon sigmoide y recto. La transformación maligna de un foco de endometriosis se estima entre el 0,3 y el 1%. El gold estándar para el diagnóstico es la resección y estudio histológico. La radioterapia y quimioterapia adyuvante todavía no ha demostrado su clara utilidad.